According to the Pharmaceutical Research and Manufacturers of America, a trade group that represents large drug companies, four out of five drugs that enter Phase 1 never make it to market, failing because they are too toxic or turn out to be ineffective.
pAkt1 was down-regulated just as cells enter phase 1, but levels were rapidly restored at day 2 of differentiation, and maintained throughout the endodermal differentiation.
Moreover, only 8% of CNS drugs that enter phase 1 are approved, with about 65% of the failures due to lack of efficacy or sufficient differentiation in phase III.
Of the 5637 eligible patients, 61% (3460) opted into the service, 58% (3249) attended for assessment, 3 were deemed ineligible at assessment because their BMI was lower than 30 kg/m, 38% (2153) opted to enter phase 1 and 34% (1916) attended phase 1 at least once.
The animal had no choice other than completing the sequence and only after completing the total sequence, the animal could either repeat a part of Phase 3 (15%), or enter Phase 2 again (35%) or, under our experimental conditions, enter Phase 1 again (50%).
There remain several important challenges for the IMPC as we enter Phase 1, and as we ramp up for Phase 2. First, we must improve the phenotyping pipeline, continually assessing the productivity and sensitivity of phenotyping platforms and introducing alternative tests where necessary.
